Introduction {#sec1}
============

Breast cancer (BC) is the second, after lung cancer (40--50%), most common cause of brain metastases (brain metastases from breast cancer -- BMF-BC) (15--25%), and in this respect it comes before melanoma (5--15%) and renal and colorectal cancers \[[@cit0001]--[@cit0006]\]. At diagnosis of a BC of a locoregional extent, the risk of BMF-BC development is about 5% \[[@cit0004], [@cit0007]--[@cit0009]\], but in patients with a generalized BC it reaches 7--17% \[[@cit0001], [@cit0002], [@cit0004], [@cit0007], [@cit0009]--[@cit0012]\], and in 1.3% of patients BMF-BC are the first symptom of a metastatic disease \[[@cit0007], [@cit0009]\]. At autopsy, BMF-BC are found in about 30% of patients who died of BC, and in the group of patients with metastatic disease in 6 or more locations this percentage rises up to 86% \[[@cit0001], [@cit0002], [@cit0004]\]. The incidence of BMF-BC is systematically increasing due to: increasing incidence of cancers related to population ageing, improved survival of BC patients associated with adjuvant treatment and better efficacy of systemic treatment of generalised BC, and also due to the progress in imaging technology (CT, MRI, PET) \[[@cit0001], [@cit0003], [@cit0005], [@cit0010], [@cit0013]\].

BMF-BC usually develop in late, advanced stages of the neoplastic process and in general they are preceded by extracranial distant metastases, e.g. bone, liver or lung metastases \[[@cit0002], [@cit0004], [@cit0005], [@cit0014]\]. Median time between BC diagnosis and BMF-BC occurrence is 2--3 years and varies significantly between different BC subtypes, as follows: 28, 36, 47 and 54 months for triple negative, HER2+, luminal B and luminal A disease, respectively \[[@cit0001], [@cit0015]--[@cit0019]\].

Particular molecular subtypes of breast cancer have different predilection for brain metastasis (BM) and thereby different effect on life expectancy. TNBC and HER2+ patients have the worst prognosis \[[@cit0020], [@cit0021]\]. The situation has changed recently when the transtuzumab therapy has become widely available, that improves OS in this group of patients. Both these types of cancer show particularly high incidence of intracranial spread, reaching: 25--46% in the TNBC population and 15--44% in the HER2+ population \[[@cit0021]--[@cit0024]\].

Numerous risk factors for BMF-BC occurrence are known, such as: age less than 50 years, negative hormone receptor status, HER2 over-expression, high (G3) tumour grade, regional lymph node metastases, advanced extracranial disease (distant metastases in more than 2 locations), presence of BRCA 1 mutation, high level of Ki-67 expression, etc. \[[@cit0001]--[@cit0004], [@cit0007], [@cit0010], [@cit0012], [@cit0025]--[@cit0029]\]. In the group of patients with generalised BC, the risk of BMF-BC occurrence is clearly related to the histological BC subtype and is 35% for HER2+ tumours, 20% for triple negative disease and only 3% for luminal A breast cancer \[[@cit0030], [@cit0031]\].

In general, anty-HER 2 treatment does not reduce the incidence of BMF-BC, however it delays their occurrence (13 months vs. 2 months) and improves survival (11.6 vs. 6.1 months) \[[@cit0013], [@cit0032]\].

General treatment results {#sec2}
=========================

Development of BMF-BC is associated with unfavourable prognosis \[[@cit0001], [@cit0003]--[@cit0005], [@cit0007], [@cit0015], [@cit0033]--[@cit0036]\], and median survival ranges from 2 to 16 months, depending on many prognostic factors (age and performance status of the patient, molecular cancer subtype, extracranial disease extent, number of BMF-BC, BMF-BC-free survival and treatment used \[[@cit0001]--[@cit0003], [@cit0005], [@cit0012], [@cit0015], [@cit0016], [@cit0035], [@cit0036]\]. Recursive partitioning analysis (RPA) index, developed by Gaspar *et al.* \[[@cit0037]\], is also a prognostic factor. Aoyama performed analysis of 16 publications presenting the results of brain metastases treatment with various methods; 7 publications pertained to metastases from various cancers, among which BMF-BC constitutes only 10--18%, 2 publications included only non small-cell lung cancer (NSCLC) metastases, and next 7 publications -- only BMF-BC \[[@cit0038]\]. Aoyama's analysis has shown that the median survival time for breast cancer and other cancers was similar and was: 17.6 and 14.6 months for RPA class I, 10.6 and 10.1 month for RPA class II, and 3.0 and 4.4 months for RPA class III, respectively ([Table 1](#t0001){ref-type="table"}). It should be stressed that about 20% of patients with BMF-BC survive 12 months since their occurrence \[[@cit0003]--[@cit0005], [@cit0016], [@cit0033], [@cit0034]\].

###### 

RTOG devised prognostic groups

  -----------------------------------------------------------------------------------------------------------
  Classes                                                                          Median survival (months)
  ----------- -------------------------------------------------------------------- --------------------------
  Class I     K ≥ 70\                                                              7.1
              \< 65 years of age with primary control no extracranial metastases   

  Class II    all others                                                           4.2

  Class III   K \< 70                                                              2.3
  -----------------------------------------------------------------------------------------------------------

Median survival of untreated patients with BMF-BC is slightly more than 1 month, of patients receiving palliative corticosteroid treatment -- up to 2 months, of patients subject to WBRT -- 3--6 months, and extends to 10--12 months in the group of patients with 1--3 BMF-BC treated with surgery or stereotactic radiosurgery (SRS) with or without subsequent whole brain radiotherapy (WBRT) \[[@cit0001], [@cit0016], [@cit0039]\].

Treatment methods {#sec3}
=================

The following methods are used in the treatment of BMF-BC: surgery, SRS, WBRT, systemic treatments and various combinations of these methods ([Tables 2](#t0002){ref-type="table"}, [3](#t0003){ref-type="table"}) \[[@cit0005], [@cit0007], [@cit0026], [@cit0038]--[@cit0050]\]. In general, local (surgery, SRS) \[[@cit0005], [@cit0007], [@cit0038], [@cit0040], [@cit0046]--[@cit0049]\] or regional (WBRT) \[[@cit0005], [@cit0007], [@cit0038], [@cit0039], [@cit0042], [@cit0043], [@cit0050]\] treatment is preferred, or combination of surgery and radiotherapy. There is a growing role of systemic treatments, in particular of targeted therapies \[[@cit0005], [@cit0007], [@cit0026], [@cit0043]--[@cit0047]\].

###### 

Single brain metastasis ASTRO guideline

  Survival time -- 3 month or more                                                                                                                                   Survival time -- less than 3 month
  -------------------------------------------------- -------------------------------------------------- ------------------------------- ---------------------------- ------------------------------------
  Resectable Good prognosis                                                                             Not resectable Good prognosis                                Poor prognosis
  Metastasis size ≤ 3--4 cm                          Metastasis size \> 3--4 cm                         Metastasis size ≤ 3--4 cm       Metastasis size \> 3--4 cm   
  Surgery and WBRT                                   Surgery and WBRT                                   Radiosurgery and WBRT           WBRT                         WBRT
  Radiosurgery and WBRT                              Surgery with radiosurgery/radiation boost ± WBRT   Radiosurgery                                                 Palliative care
  Radiosurgery                                                                                                                                                       
  Surgery with radiosurgery/radiation boost ± WBRT                                                                                                                   

###### 

Multiple brain metastasis ASTRO guideline

  Survival time -- 3 month or more                                          Survival time -- less than 3 month
  ---------------------------------- -------------------------------------- ------------------------------------
  All brain metastases ≤ 3--4 cm     Brain metastases causing mass effect   
  Radiosurgery and WBRT              Surgery and WBRT                       WBRT
  Radiosurgery                       WBRT                                   Palliative care
  WBRT                                                                      

Local treatment {#sec3.1}
---------------

There are no controlled clinical studies entirely dedicated to the treatment of BMF-BC; in phase III studies conducted so far, the most prevalent group, 52.4--77% was the group of patients with brain metastases from NSCLC, and only 6.8--19% of patients had BMF-BC \[[@cit0007], [@cit0038]\]. These studies have shown that local treatment (surgery, SRS) used as an add-on to WBRT improves local control in patients with 1--3 BMF-BC and survival of patients with single BMF-BC. It was also found that WBRT adjuvant to the local treatment in patients with 1--3 BMF-BC significantly increases brain disease control but has no significant effect on patients' survival.

### Surgery

The best candidates for surgery are patients:

-   with a single BMF-BC at a surgically accessible location,

-   aged \< 65 years,

-   with Karnofsky score (KPS) of 70 or more,

-   with cured or controlled extracranial disease.

Irrespective of the extracranial disease control status, there are indications for surgery in:

-   the rare breast cancer patients with an isolated BMF-BC (the only evidence of the disease),

-   patients with symptomatic mass effect (tumour diameter larger than 3 cm),

-   patients with obstructive hydrocephalus from their BMF-BC or at high risk for obstructive hydrocephalus from a large posterior fossa BMF-BC abutting the fourth ventricle \[[@cit0042], [@cit0051], [@cit0052]\].

### Stereotactic radiosurgery

Similarly as for surgical treatment, patients with a single BMF-BC, with a KPS of 70 and more, with cured or controlled extracranial disease are the best candidates for SRS; in this setting, the efficacy of SRS is similar to that of surgery \[[@cit0051]\]. SRS has however some advantages:

-   it is not limited by BMF-BC location in the brain and it may be used in all cerebral regions, including those not accessible to surgery (e.g. the brainstem),

-   the number of lesions is not a limiting factor for SRS if each lesion is small and adequate doses can be delivered (15--24 Gy),

-   possible active extracranial disease is not a contraindication for SRS,

-   multiple BMF-BC may be treated in one outpatient session,

-   it does not interfere with ongoing systemic treatment,

-   it does not require general anaesthesia or hospitalisation,

-   there is no risk of craniotomy-related complications.

A limitation of SRS, in contrast to surgery, is its unsuitability for the treatment of BMF-BC lesions exceeding 3--3.5 cm in the largest diameter. Additionally, surgery can immediately relieve symptomatic mass effect and it usually guarantees more complete and faster resolution of vasogenic edema \[[@cit0004], [@cit0038], [@cit0048]--[@cit0052]\].

A disadvantage of SRS, as compared to WBRT, in patients with BMF-BC, is the subsequent development of new lesion in the non-irradiated field \[[@cit0007], [@cit0049], [@cit0053]\]. On the other hand, WBRT causes the problem of late neurotoxicity \[[@cit0007], [@cit0054], [@cit0055]\]; Chang *et al.* compared the neurocognitive results of SRS alone versus SRS plus WBRT in a randomized controlled trial of 1--3 newly diagnosed brain metastases; patients who underwent SRS plus WBRT were at a greater risk of a significant decline in learning and memory function by 4 months \[[@cit0054]\]. Abe and Aoyama tried to define patients with brain metastases with a longer survival prognosis, in whom it would be possible to avoid adjuvant WBRT following SRS \[[@cit0055], [@cit0056]\].

In the analysis of 17 publications cited above, Aoyama \[[@cit0038]\] has shown that:

-   the percentage of patients with RPA III (very poor outcome) was higher in studies including breast cancer patients than in those including brain metastases of any origin (median percentage 42% vs. 10%),

-   the percentage of patients with RPA III was low in studies in which SRS was the predominant treatment method, as compared with those in which WBRT was the main method; it is clear that SRS was used only for highly selected patients.

Aoyama suggests using SRS alone only in patients with single BMF-BC and KPS ≥ 70, provided that the patient remains under regular and frequent follow-up \[[@cit0007], [@cit0038]\].

The risk of distant brain failure after SRS alone seems to be much higher in patients with triple negative breast carcinoma \[[@cit0057]\].

Leptomengeal disease (LMD) in breast cancer patients with CSN metastases is associated with poor prognosis and represents the terminal stage of the disease. LMD diagnosis is confirmed by cerebrospinal fluid cytology or MRI images. There were attempts to identify the risk factors of disease spread (to the CSN). The analyses performed have shown that only the presence of active disease within the chest (i.e. lung metastases) is associated with disease spread to the CSN. Some authors suggest a secondary hematogeneous spread from pulmonary reservoir. Receptor status, active liver and bone metastases, tumour morphology, tumor size, number of brain metastases and history of WBRT showed no correlation with LMD \[[@cit0058]\]. SRS offers good local control and reduces the risk of late toxicity, as compared to other treatment methods but it cannot protect the patient from meningeal spread \[[@cit0059]--[@cit0061]\]. Mean overall survival from LMD diagnosis is approximately 6 months \[[@cit0058]\].

### Whole brain radiotherapy

When WBRT is used as adjuvant treatment of BMF-BC after surgery or SRS, two aspects should be taken into consideration: on one hand, this is late neurotoxicity of WBRT, and on the other hand -- the risk of development of brain metastases outside the region treated locally; the latter one is of particular importance in breast cancer patients \[[@cit0007], [@cit0038], [@cit0051], [@cit0055], [@cit0062], [@cit0063]\].

WBRT alone is indicated first of all in patients not amenable to surgery or SRS, with KPS \< 70, with numerous BMF-BC, and with uncontrolled extracranial disease \[[@cit0007], [@cit0050], [@cit0051], [@cit0064]\]. None of the WBRT fractioning regimens has shown a clear advantage; however fraction doses exceeding 3 Gy are decidedly avoided, due to an increased risk of late post-irradiation neurological damage \[[@cit0007], [@cit0050], [@cit0051], [@cit0065]\]. The regimen of 30 Gy administered in 10 fractions over a period of 2 weeks is the most commonly used \[[@cit0007], [@cit0050], [@cit0051]\]. In the group of patients with BMF-BC some authors use lower fraction doses, administering the total dose of 40 Gy in 20 fractions (fraction dose -- 2 Gy) \[[@cit0050], [@cit0051]\]. The rationale for such fractionation is the possibility of reduction of the risk of late radiation-induced encephalopathy with neurocognitive disturbances that is main late complication of WBRT \[[@cit0050], [@cit0051], [@cit0066], [@cit0067]\]. It should be stressed that breast cancer is a relatively radiosensitive tumour; additionally, patients with generalised breast cancer live currently much longer, owing to effective systemic treatment which increases the risk of emergence of late post-irradiation injuries \[[@cit0050], [@cit0051]\].

Median survival after WBRT ranges from 3 to 6 months, and objective response to the treatment of BMF-BC is achieved in 30--60% of patients \[[@cit0007], [@cit0041], [@cit0050], [@cit0068]\].

However in about one half of patients undergoing WBRT it is not effective enough and these patients die of BMF-BC progression \[[@cit0050], [@cit0051], [@cit0064]\]. Nieder *et al.* suggest that frequency and duration of response to WBRT is higher in patients with breast cancer, as compared to patients with e.g. non small cell lung cancer, renal cancer or melanoma \[[@cit0068]\]. There are ongoing studies on reduction of WBRT toxicity by using e.g. irradiation technique with hippocampus shielding, intensity modulated radiotherapy, neuroprotectors, and on enhancement of WBRT efficacy by its combination with systemic treatment \[[@cit0007], [@cit0026], [@cit0045], [@cit0050], [@cit0064]\].

One year or more after WBRT patients treated with this method start to present symptoms of late radiation toxicity to the white matter. This includes demyelination and injury to the population of periventricular stem cells responsible for repair processes within the CSN. White matter changes (WMC) manifest as neurocognitive decline, memory and behaviour disturbances, reaction slow-down and predilection for substances of abuse \[[@cit0069]\]. WMC diagnosis is based on imaging findings. White matter damage is visible T2 -- weighed or FLAIR MRI scans in more than 70% of (irraditated) patients. In patients receiving SRS these lesions occur significantly less frequently \[[@cit0070]\]. Women with 1--3 intracranial metastases demonstrated remarkably higher neurotoxicity after WBRT plus SRS than women who were treated with SRS alone \[[@cit0071]\]. Some recent reports show that the irradiated volume has a higher effect on survival than the number of irradiated metastases \[[@cit0072]\]. Along with metastatic breast cancer patient survival prolongation, availability of new treatment technologies and possibility to combine or repeat treatments, the issue of neurotoxicity becomes more and more serious \[[@cit0073]\].

In conclusion, the majority of the BMF-BC patients are not good candidates to surgery or SRS, and WBRT alone or combined with a systemic treatment still plays a major role in the treatment of these patients.
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